Table 6 Attrition rate (DiMasi et al. 2010)

♦ Preclinical to IND: 70 %

Start

End

Probability

♦ Phase I to Phase 2: 71 %

PC

Approval

13.3 %

♦ Phase 2 to Phase 3: 45 %

P1

Approval

19.0 %

♦ Phase 3 to NDA/BLA: 64 %

P2

Approval

26.8 %

♦ NDA/BLA to approval: 93 %

P3

Approval

59.5 %

NDA/BLA

Approval

93.0 %